Explore

Steve and Marian Mosites Family Foundation Funds Precision Medicine Research in Head and Neck Cancer

Steve and Marian Mosites Family Foundation Funds Precision Medicine Research in Head and Neck Cancer

The Department of Otolaryngology-Head & Neck Surgery has received a significant gift from the Steve and Marian Mosites Family Foundation. This donation is specifically allocated to advance precision medicine research in head and neck cancer, funding two projects through the Mosites Precision Medicine Awards for 2026. The award recipients are Matthew Spector, MD, FACS, for his project titled 'Personalized Implant-Radiation Strategies for Head and Neck Cancer Reconstruction,' and Lazar Vujanovic, PhD, for his project 'Defining the Postoperative Immune Landscape in Oral Cavity Cancer via Surgical Drain Fluid.' Dr. Spector's research aims to explore personalized mandibular reconstruction using novel CFR-PEEK implants to improve radiation delivery and healing. Dr. Vujanovic's project will study the immune environment immediately after surgery using surgical drain fluid to understand anti-tumor immune responses and identify patients who might benefit from more personalized treatments. The initiative honors Maria...

Lustgarten Foundation Scientific Advisory Board Outlines Strategic Direction for Pancreatic Cancer Treatments

Lustgarten Foundation Scientific Advisory Board Outlines Strategic Direction for Pancreatic Cancer Treatments

The Lustgarten Foundation, the largest private funder of pancreatic cancer research, recently convened its Scientific Advisory Board (SAB) to establish the strategic direction for the next generation of pancreatic cancer treatments. Following a year of significant scientific progress, including the FDA approval of the RAS-targeted therapy RASONQUE™ (daraxonrasib), the meeting focused on building upon these breakthroughs to develop more effective and durable treatments. Key areas of discussion included advancing methods to measure treatment response, understanding treatment failure and resistance, identifying new therapeutic targets and combinations, advancing prevention and interception strategies, and innovating clinical trial design. A central theme was the importance of integrating clinical observations, biological insights, and new methods for measuring treatment response to guide more personalized treatment strategies. The Foundation awarded $22.8 million in new research funding in fiscal year 2026, a...

Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, will receive the Precision Medicine World Conference (PMWC) Pioneer Award in January 2027. This recognition is for his significant contributions to advancing minimal residual disease (MRD) as an earlier and more precise measure of treatment effectiveness in multiple myeloma. MRD refers to the tiny number of cancer cells that remain during remission, detectable only by highly sensitive laboratory methods. Dr. Landgren's work has been instrumental in helping new therapies demonstrate effectiveness more quickly, potentially accelerating their availability to patients. His team is also leading research into bispecific T-cell therapies, including strategies to safely deliver these treatments and manage side effects like cytokine release syndrome. This research extends to other cancers, such as lymphoma and rare gynecologic neuroendocrine cancers, demonstrating a continuous cycle of measurement, learni...

Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Scientists at Rockefeller University have discovered that immunoglobulin A (IgA) antibodies in the gut play a crucial role in preventing colon cancer. Their research, published in Nature, found that mice lacking IgA developed more than twice the usual number of colon tumors. The study elucidated that IgA antibodies bind to cells lining the gut, specifically epithelial cells, and prevent them from dividing too rapidly. This uncontrolled cell division is a precursor to cancer. Senior author Daniel Mucida, head of Rockefeller's Laboratory of Mucosal Immunology, highlighted that this finding reveals a natural defense mechanism that restrains cell division before tumors can form. The research also showed that administering oral doses of IgA to IgA-deficient mice eliminated their increased risk of developing tumors.

Devon Walker Featured in The Moth's 'Funny Story' Event, Not SNL

Devon Walker Featured in The Moth's 'Funny Story' Event, Not SNL

Devon Walker Featured in The Moth's 'Funny Story' Event, Not SNL

European Innovation Council Funds Research for mRNA Liver Cancer Vaccine Development

European Innovation Council Funds Research for mRNA Liver Cancer Vaccine Development

The European Innovation Council (EIC) has allocated approximately €3.8 million in funding to the international research project ADVANCE. This project, involving Universitatsmedizin Frankfurt, aims to develop an mRNA-based cancer vaccine for hepatocellular carcinoma (HCC), the most common form of liver cancer. The vaccine is designed to train the immune system to recognize novel target structures, specifically 'dark peptides' that become more prevalent in tumor cells under cellular stress, but are largely absent from healthy tissue. Researchers, including Dr. Andreas Schlosser from Universitatsmedizin Frankfurt, are using mass spectrometry, RNA sequencing, and artificial intelligence to identify these tumor-specific peptides. The mRNA containing instructions for producing these peptides will be encapsulated in lipid nanoparticles for delivery, aiming to trigger a targeted T-cell response to attack liver cancer cells. This initiative seeks to overcome the challenge of cancer cells evading immune surveillance...

Hoag Researchers Discover Hidden Molecular Warning for Ovarian Cancer, Enabling Earlier Detection

Hoag Researchers Discover Hidden Molecular Warning for Ovarian Cancer, Enabling Earlier Detection

Researchers at Hoag have made a groundbreaking discovery of a molecular warning signal in the blood that can identify serous tubal intraepithelial carcinoma (STIC), an early, precancerous stage of high-grade serous ovarian cancer (HGSOC). This breakthrough, led by Dr. Rajan Gogna and Dr. Esha Madan, was published in Nature Medicine on November 10, 2026. Ovarian cancer is often diagnosed at advanced stages, making this early detection method particularly significant. HGSOC frequently originates in the fallopian tube as STIC, which consists of microscopic, non-invasive abnormal cells undetectable by current imaging or conventional blood tests. The study found elevated blood levels of Tu-Stroma, an RNA molecule linked to cancer cell growth, in women with both STIC and early-stage HGSOC. This discovery suggests a potential to detect ovarian cancer development years before traditional methods.

Comics Come Home 30 Event Features All-Star Lineup and Community Impact

Comics Come Home 30 Event Features All-Star Lineup and Community Impact

Comics Come Home 30 Event Features All-Star Lineup and Community Impact

Jon Stewart skewers liberals, conservatives at Stand Up for Heroes event

Jon Stewart skewers liberals, conservatives at Stand Up for Heroes event

At the 20th "Stand Up for Heroes" event benefitting the Bob Woodruff Foundation, Jon Stewart joked about both Republicans and Democrats.

Precision for Medicine Seeks Clinical Trial Manager for Oncology Research

Precision for Medicine Seeks Clinical Trial Manager for Oncology Research

Precision for Medicine Seeks Clinical Trial Manager for Oncology Research

Joyce DeWitt Reflects on 'Three's Company' Partnership with John Ritter, Citing "Absolute Trust"

Joyce DeWitt Reflects on 'Three's Company' Partnership with John Ritter, Citing "Absolute Trust"

Joyce DeWitt Reflects on 'Three's Company' Partnership with John Ritter, Citing "Absolute Trust"

Comedian Shane Gillis's Controversial SNL Hosting Stirs Debate Over Network Comedy Standards

Comedian Shane Gillis's Controversial SNL Hosting Stirs Debate Over Network Comedy Standards

Comedian Shane Gillis's Controversial SNL Hosting Stirs Debate Over Network Comedy Standards